Live
- ICC Champions Trophy: PCB appoints Chief Operating Officer; reiterates stand to host Champions Trophy entirely in Pakistan
- Probe initiated after food poisoning incident
- BGT 2024-25: Nitish Kumar Reddy, Harshit Rana make India Test debuts in first Border-Gavaskar Trophy in Perth
- 100 students fall sick after consuming contaminated food
- TCS will commence ops in Visakha in 3 months: Lokesh
- Pawan, 2 other ministers rule out VSP privatisation
- HC Bench In Kurnool: House passes unanimous resolution
- Low Pressure Area Likely in Southeast Bay of Bengal, Heavy Rains Forecasted for AP
- Malabar Gold & Diamonds launches new gold jewellery
- Collector reviews arrangements for Guv’s visit
Granules gets USFDA nod for ADHD drug
Highlights
Drug firm Granules India on Monday said its subsidiary has received approval from the US health regulator for Methylphenidate Hydrochloride
Hyderabad: Drug firm Granules India on Monday said its subsidiary has received approval from the US health regulator for Methylphenidate Hydrochloride extended-release capsules, used for the treatment of attention deficit hyperactivity disorder (ADHD).
The approved product is bioequivalent to the reference listed drug product (RLD), Ritalin LA extended-release capsules of Novartis Pharmaceuticals Corporation.
The US Food and Drug Administration (USFDA) has approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals, a wholly-owned foreign subsidiary of Granules India, for Methylphenidate Hydrochloride extended-release capsules in the strengths of 10 mg, 20 mg, 30 mg, 40 mg and 60 mg, Granules said.
Next Story
ADVERTISEMENT
